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The effect of BCG revaccination on all-cause mortality 
beyond infancy: 30-year follow-up of a population-based, 
double-blind, randomised placebo-controlled trial in Malawi
Judith R Glynn, Albert Dube, Katherine Fielding, Amelia C Crampin, Karonga Prevention Trial Group*, Chifundo Kanjala, Paul E M Fine
Summary
Background Trials of BCG vaccination to prevent or reduce severity of COVID-19 are taking place in adults, some of 
whom have been previously vaccinated, but evidence of the beneficial, non-specific effects of BCG come largely from 
data on mortality in infants and young children, and from in-vitro and animal studies, after a first BCG vaccination. 
We assess all-cause mortality following a large BCG revaccination trial in Malawi.
Methods The Karonga Prevention trial was a population-based, double-blind, randomised controlled in Karonga 
District, northern Malawi, that enrolled participants between January, 1986, and November, 1989. The trial compared 
BCG (Glaxo-strain) revaccination versus placebo to prevent tuberculosis and leprosy. 46 889 individuals aged 3 months 
to 75 years were randomly assigned to receive BCG revaccination (n=23 528) or placebo (n=23 361). Here we report 
mortality since vaccination as recorded during active follow-up in northern areas of the district in 1991–94, and in a 
demographic surveillance follow-up in the southern area in 2002–18. 7389 individuals who received BCG (n=3746) or 
placebo (n=3643) lived in the northern follow-up areas, and 5616 individuals who received BCG (n=2798) or placebo 
(n=2818) lived in the southern area. Year of death or leaving the area were recorded for those not found. We used 
survival analysis to estimate all-cause mortality.
Findings Follow-up information was available for 3709 (99·0%) BCG recipients and 3612 (99·1%) placebo recipients 
in the northern areas, and 2449 (87·5%) BCG recipients and 2413 (85·6%) placebo recipients in the southern area. 
There was no difference in mortality between the BCG and placebo groups in either area, overall or by age group or 
sex. In the northern area, there were 129 deaths per 19 694 person-years at risk in the BCG group (6·6 deaths per 
1000 person-years at risk [95% CI 5·5–7·8]) versus 133 deaths per 19 111 person-years at risk in the placebo group 
(7·0 deaths per 1000 person-years at risk [95% CI 5·9–8·2]; HR 0·94 [95% CI 0·74–1·20]; p=0·62). In the southern 
area, there were 241 deaths per 38 399 person-years at risk in the BCG group (6·3 deaths per 1000 person-years at risk 
[95% CI 5·5–7·1]) versus 230 deaths per 38 676 person-years at risk in the placebo group (5·9 deaths 
per 1000 person-years at risk [95% CI 5·2–6·8]; HR 1·06 [95% CI 0·88–1·27]; p=0·54).
Interpretation We found little evidence of any beneficial effect of BCG revaccination on all-cause mortality. The high 
proportion of deaths attributable to non-infectious causes beyond infancy, and the long time interval since BCG for 
most deaths, might obscure any benefits.
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Introduction
There is considerable interest in the non-specific beneficial 
effects of the tuberculosis vaccine, BCG, on response to 
other infections. Ecological studies and BCG’s immuno-
logical effects have suggested that BCG vaccination 
might be of use in the COVID-19 pandemic.1–3 A search 
of ClinicalTrials.gov shows that there are 17 randomised 
controlled trials comparing BCG versus placebo to reduce 
incidence or severity of COVID-19, aiming to recruit several 
thousand participants.
Most of the evidence of non-specific benefit of BCG 
vaccination comes from studies of all-cause mortality 
in neonates and young children receiving their first 
BCG vaccination, with very scarce data in adults.1,4 Yet, 
for the COVID-19 trials, the participants are adults, 
who will often have received a BCG vaccination in 
the past.
In populations in which a high proportion of deaths are 
due to infections, any beneficial effect of BCG vaccination 
on all-cause mortality might be seen in older children and 
adults, as well as in young children. Because those who 
receive or do not receive a BCG vaccination in routine 
programmes are likely to have different socioeconomic 
backgrounds and health-seeking behaviour,5 and so 
different mortality risks, findings from observational data 
that might generate hypotheses on the non-specific effects 
of BCG vaccination require substantiation by randomised 
trials.4
Of the trials included in a systematic review of the effect 
of BCG vaccination on tuberculosis,6 only four trials that 
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included vaccination in individuals older than 5 years 
reported any data on mortality. None of the four trials 
show any effect of BCG vaccination on non-tuberculosis 
mortality (appendix pp 2–3).7–10 In Chingleput, south 
India,7 and among Native Americans in the USA,9 data 
were shown (but not analysed), allowing survival curves to 
be constructed. There was no evidence in either trial of 
a difference in non-tuberculosis mortality between 
vaccinated and non-vaccinated groups at any time after 
vaccination (figure 1). Two further trials provide evidence 
on mortality. In a trial in Algiers in 1935, children were 
allocated by odd or even numbers at birth registration to 
receive oral BCG at birth, and at 1, 3, and 7 years of age, or 
no BCG. All-cause mortality was similar in the two groups 
during infancy, but lower in the multiply vaccinated group 
at older ages (appendix pp 2–3).11 Interim results from a 
recent small trial of BCG vaccination in older people 
were also consistent with protection but with wide CIs 
(appendix pp 2–3).12
In northern Malawi, a large trial of repeat BCG 
vaccination versus placebo in individuals of all ages with 
BCG scars recruited participants in 1986–89.13 This trial 
showed that BCG revaccination provided 49% protection 
against leprosy, but no protection against tuberculosis. 
Using information from two periods of active follow-up, 
we assessed all-cause mortality in individuals who 
received BCG revaccination or placebo.
Methods
Study design
The Karonga Prevention Trial, in Karonga District, 
northern Malawi, was a population-based, double-blind, 
randomised controlled trial, established to assess the 
effects of BCG vaccination, with or without killed 
Mycobacterium leprae, on the incidence of leprosy and 
tuberculosis. The methods are described in detail 
elsewhere.14,15 The trial protocol was approved in 1985 by 
the Health Sciences Research Committee of the Malawi 
Ministry of Health, the Standing Committee on Research 
in Human Subjects of WHO, and the Ethics Committee 
of the London School of Hygiene & Tropical Medicine. 
Follow-up of the population has been approved in the 
context of other studies by the Health Sciences Research 
Committee of the Malawi Ministry of Health and the 
Ethics Committee of the London School of Hygiene & 
Tropical Medicine.
Participants
Recruitment took place house-to-house from January, 1986, 
to November, 1989, throughout Karonga District, following 
meetings with traditional authorities and village headmen. 
The trial was explained to each household and informed, 
oral consent sought. All residents were eligible except 
individuals younger than 3 months or born before 1914, 
and individuals with evidence of past or current leprosy or 
tuberculosis, severe malnutrition, or other severe illness. 
Older individuals could request to be included.
Randomisation and masking
All participants were examined for BCG scars as evidence 
of previous BCG vaccination. Individuals without BCG 
scars were randomly assigned to receive BCG vaccination 
alone or with killed M leprae. Participants who had BCG 
scars were randomly assigned to receive BCG vaccination 
alone, placebo, or BCG and killed M leprae. Because no 
participants without BCG scars received placebo, the data 
reported here are restricted to scar-positive individuals 
who received BCG vaccination alone or placebo.
The BCG and placebo (dextran matrix of the BCG 
vaccine) were provided by and manufactured by Glaxo, 
UK, in identical multidose vials. Random order codes for 
the vials were provided by WHO-appointed trial monitors. 
Randomisation was thus by small group rather than 
individual. Open vials were destroyed at the end of each 
day, and a mean of 6·9 doses (range 1–11) were used 
per vial. The main results were published in 1996, but the 
investigators remained masked to the vaccine codes 
until 2019.13
Research in context
Evidence before this study
BCG vaccination is used to prevent tuberculosis, but there is 
increasing evidence that it can have non-specific beneficial 
effects. A systematic review has shown a reduction in all-cause 
mortality in very young children, and other reviews have shown 
wide-ranging effects on the immune system. To find BCG trials 
that reported on mortality in older age groups, we searched 
PubMed (on July 7, 2020) with no language restrictions to find 
the most recent systematic review of the effect of BCG on 
tuberculosis (searching on “BCG” and “trial”), and followed up 
further papers from the included trials for mortality outcomes. 
BCG has been suggested as a possible intervention for COVID-19, 
but there are very few data on the effects of BCG vaccination or 
revaccination on mortality in adults.
Added value of this study
In an extended follow-up of a large, double-blind, 
randomised trial in northern Malawi of BCG vaccination 
versus placebo in individuals of all ages who had a BCG scar 
we found no evidence of any effect of BCG revaccination on 
mortality. This is in line with data from other large trials 
including adults, which showed no effect of BCG vaccination 
on non-tuberculosis mortality.
Implications of all the available evidence
There is little evidence that a repeat BCG vaccination reduces 
non-tuberculosis mortality in adults. Any non-specific 
immune modulating effects of BCG do not seem to have 
large or long-term effects in these age groups.
See Online for appendix
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Outcomes and follow-up
The trial was designed to assess the outcomes of leprosy 
and tuberculosis but for this analysis, the outcome was 
all-cause mortality among all participants who were 
included in active follow-up that occurred in two periods. 
Cause of death was not known for most of the participants.
For the follow-up study reported here, all individuals 
who had been living in four designated areas to the north 
of the district during the vaccine trial were sought in 
four different house-to-house surveys in 1991–94. These 
areas were selected because they had relatively high 
leprosy incidence. Participants who had left the areas 
were traced elsewhere in the district. If they had died, the 
year of death was recorded. If they were not found, the 
year they left the district was recorded.13,14
A demographic surveillance area was established in the 
southern part of the district in 2002–04 and continues to 
date. This area was chosen because it had some data 
available on HIV prevalence in earlier surveys and was 
close to the project campus. Individuals who had been 
living in the area during the trial and were not known (from 
other studies in the district) to have died or moved, were 
actively sought as part of the baseline census. For those 
who were reported to have died or moved, the year of death 
or leaving was recorded. Those living in the demographic 
surveillance area are monitored through monthly reporting 
of deaths and annual censuses.16,17 For the subgroup of 
participants from the southern area who were included in 
the demographic surveillance, cause of death is available 
from verbal autopsies done with household members.18 
Informed consent was obtained for the follow-up studies.
Statistical analysis
We used survival analysis to assess the effect of BCG 
revaccination on mortality, with p values calculated by the 
log-rank method, and hazard ratios (HRs) calculated 
using Cox regression. We estimated mortality from the 
date of vaccination, censoring individuals on the date 
when they were last known to be alive (or Dec 31, 2018, for 
those alive and under surveillance in the southern area). 
For individuals who had died or left, the date of death or 
departure was taken as the midpoint of the reported year, 
or halfway between the vaccination date and the end of 
the year for those who were reported to have died or left 
in the year in which they were vaccinated. For those in the 
demographic surveillance, exact dates were used. 
Analyses were done separately for the two different 
follow-up areas because of the different follow-up periods 
and procedures. Using an intention-to-treat approach, for 
each area we assessed the effect of BCG revaccination on 
mortality overall, in different age groups at vaccination 
(<5 years, 5–14 years, 15–24 years, and 25–75 years), and 
by sex.
For the subgroup included in the demographic survei-
llance, a further analysis considered cause-specific 
mortality, estimated from the time the participants were 
first seen in the demographic surveillance. All analyses 
used STATA/IC version 16.1.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
For the original study, 121 427 participants were re-
cruited from January, 1986, to November, 1989. As 
previously reported, 5757 individuals were not eligible 
and 5835 refused to participate and were therefore not 
vaccinated as part of the trial.13 Individuals included in 
the follow-up analyses are summarised in figure 2. The 
characteristics of those included in the trial and in 
the two follow-up areas are shown in the table, and 
the characteristics of those who were not seen 
after vaccination or who were recorded as having 
Figure 1: Mortality over time in published trials of BCG versus placebo
(A) In Chingleput, south India (follow-up every 2·5 years). 7 (B) Among Native Americans, USA (annual follow-up).9 
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left during the follow-up are summarised in the 
appendix (pp 4–5).
The areas covered in the northern surveys in 1991–94 
included 3746 (15·9%) of the 23 528 individuals who had 
received BCG and were eligible for follow-up and 
3643 (15·6%) of the 23 361 who had received placebo and 
were eligible for follow-up. Follow-up information was 
available at some point after vaccination for 7321 (99·1%) 
of the 7389 participants living in the northern area during 
the follow-up period (figure 2). In the northern area, there 
was no difference in mortality between those who 
received BCG and those who received placebo: there were 
129 deaths per 19 694 person-years at risk in those who 
had received BCG (6·6 deaths per 1000 person-years at 
risk [95% CI 5·5–7·8]) and 133 deaths per 19 111 person-
years at risk in those who had received placebo (7·0 deaths 
per 1000 person-years at risk [95% CI 5·9–8·2]; HR 0·94 
[95% CI 0·74–1·20]; p=0·62). There was no difference 
between the BCG revaccination and placebo groups in 
any age group (likelihood test for interaction by age 
group, p=0·98; figure 3). There was also no difference by 
sex (likelihood test for interaction p=0·74; appendix p 6).
The demographic surveillance site covered an area in 
the southern part of the district. Of the 46 889 BCG scar-
positive individuals who received BCG or placebo, 
5616 (12·0%) were living in this area during the trial 
recruitment. We had follow-up information at some point 



















Age at vaccination, years
<5 3598 (15·3%) 3542 (15·2%) 610 (16·5%) 604 (16·7%) 269 (11·0%) 249 (10·3%)
5–14 9692 (41·2%) 9704 (41·5%) 1521 (41·0%) 1516 (42·0%) 1043 (42·6%) 1030 (42·7%)
15–24 5911 (25·1%) 5926 (25·4%) 830 (22·4%) 822 (22·8%) 705 (28·8%) 684 (28·4%)
25–75 4327 (18·4%) 4189 (17·9%) 748 (20·2%) 670 (18·6%) 432 (17·6%) 450 (18·7%)
Sex
Male 11 670 (49·6%) 11 545 (49·4%) 1859 (50·1%) 1833 (50·8%) 1199 (49·0%) 1191 (49·4%)
Female 11 858 (50·4%) 11 816 (50·6%) 1850 (49·9%) 1779 (49·3%) 1250 (51·0%) 1222 (50·6%)
Table: Baseline characteristics of those in the Karonga Prevention Trial, overall and among those with 
follow-up information in the two areas
3746 received BCG
 37 no follow-up
 3128 alive
 129 died
 452 left area
2798 received BCG
 349 no follow-up
 1620 seen
 241 died
 588 left area
3643 received placebo
 31 no follow-up
 2955 alive
 133 died
 524 left area
2818 received placebo
 405 no follow-up
 1542 seen
 230 died
 641 left area
1173 included in demographic 
           surveillance (from 2002)
 736 alive
 111 died
 326 left area
1190 included in demographic 
            surveillance (from 2002)
 716 alive
 104 died
 370 left area
5616 living in southern follow-up area7389 living in northern follow-up area 
46 889 scar-positive and eligible for follow-up
 23 528 received BCG
 23 361 received placebo
33 788 living outside follow-up areas*
 16 920 received BCG
 16 868 received placebo
121 427 vaccinated in original trial
74 538 excluded
 74 378 scar-negative or received BCG with killed Mycobacterium leprae
 112 vaccinated with two different non-placebo vaccines
 48 doubtful vaccine code
Figure 2: Flow diagram of follow-up of Karonga Prevention Trial, Malawi
Alive=alive and seen when sought in survey. Died=reported dead when sought. Left area=reported to have left the district (in northern surveys) or the area (in southern 
survey). Seen=seen at least once after vaccination. *28 participants who received BCG and 32 who received placebo were included in both follow-ups because they had 
moved during the trial.
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after vaccination for 4862 (86·6%), nearly half of whom 
were seen in the demographic surveillance (figure 2). 
There was no difference in mortality by vaccine 
status in the southern area: there were 241 deaths 
per 38 399 person-years at risk in those who received BCG 
(6·3 deaths per 1000 person-years at risk [95% CI 
5·5–7·1]) compared with 230 deaths per 38 676 person-
years at risk in those who received placebo (5·9 deaths 
per 1000 person-years at risk [95% CI 5·2–6·8]; HR 1·06 
[95% CI 0·88–1·27]; p=0·54). There was no difference in 
survival between BCG and placebo groups in any age 
group (likelihood test for interaction by age group p=0·75; 
figure 4) or by sex (likelihood test for interaction p=0·24; 
appendix p 4).
In the subgroup of the southern population who were still 
alive and living in the area during the period of demographic 
surveillance (2002–18), there were no differences between 
the BCG and placebo groups in all-cause mortality, mortality 
Figure 3: Mortality by BCG revaccination status in northern area of Karonga District, to 1994
(A) All age groups. (B) Population younger than 5 years at vaccination. (C) Population aged 5–14 years at vaccination. (D) Population aged 15–24 years at 
vaccination. (E) Population aged 25–75 years at vaccination. HR=hazard ratio.
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excluding external causes, mortality due to communicable 
disease, or mortality due to communicable diseases other 
than HIV/AIDS and tuberculosis (appendix p 7).
Discussion
We found no evidence of an effect of revaccination with 
BCG on all-cause mortality, either overall or in any age 
group. Importantly, we also found no evidence of any 
detri mental effect. A high proportion of individuals were 
followed up at least once after vaccination, and as the 
data come from a double-blind, randomised controlled 
trial, confounding and bias (eg, by socioeconomic status 
or health seeking behaviour) should be minimal.
We relied on reported years of death and of departure 
from the area, so there might have been some inaccuracy 
in dates of events (for both BCG and placebo groups). It 
is possible that some deaths were missed among those 
with incomplete follow-up information. In the northern 
Figure 4: Mortality by BCG revaccination status in southern area of Karonga District, to 2018
(A) All age groups. (B) Population younger than 5 years at vaccination. (C) Population aged 5–14 years at vaccination. (D) Population aged 15–24 years at vaccination. 
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area, almost everyone had some follow-up information, 
but the proportion who were reported to have left the 
district during follow-up was higher in the placebo group 
than the BCG group (figure 2; appendix p 4). In the 
southern area, the proportion with no follow-up and the 
proportion who were reported to have left the area during 
follow-up were both slightly higher in the placebo group 
(figure 2; appendix p 4–5). In both areas, the imbalance 
in those who had left between the placebo and BCG 
groups was only seen in those vaccinated as children 
(younger than 5 years in both areas, and also aged 
5–14 years in the northern area; appendix pp 4–5).
If those who were not seen for follow-up after 
revaccination or were reported to have left the area were 
more likely to have died, then it is possible that this could 
have masked some non-specific beneficial effect of repeat 
BCG vaccination on mortality in those revaccinated as 
children. We analysed data from the northern and 
southern areas separately because of the different 
follow-up periods and methods. The data from the 
northern area are likely to be more accurate than those 
from the southern area because of the shorter period of 
recall for dates, and a more exhaustive search for those in 
the trial. In the southern area, deaths could have been 
missed among those with no records following 
vaccination, but the proportion with no follow-up was only 
slightly higher in the placebo group than in the vaccination 
group (appendix p 5). The most intensive follow-up was 
from 2002 among those in the demographic surveillance 
area in the south. Migration and death should have been 
reported accurately in this group so the slightly higher 
proportion of placebo recipients than BCG recipients who 
were reported to have left is likely to be due to chance, not 
misclassification. Differences in follow-up are very 
unlikely to explain the absence of an association between 
repeat BCG vaccination and mortality in adults.
Neonates were not included in this study and there is 
little evidence in other studies of benefit from BCG on all-
cause mortality in children vaccinated at older ages,4 or in 
adults (appendix pp 2–3).7–10 In some studies in children, 
the order of vaccines has been found to influence the 
effect on mortality, and subsequent vaccines could 
theoretically influence the results.19 However, in our trial, 
very few individuals would have received subsequent 
vaccines. The first polio national immunisation day was 
in 199620 and, as these target children up to 5 years old, 
they would not have included the BCG vaccination trial 
population. The first measles vaccination campaign was 
in 1998 and targeted individuals up to 15 years old,21 so 
would only have included the very youngest age group in 
the southern analysis.
It has been suggested that the non-specific effects of 
BCG vaccination might vary by strain, and that this could 
explain the reduction in infant all-cause mortality seen in 
trials in Guinea-Bissau using BCG-Denmark, and not in 
India using BCG-Russia.22 The strain used in this study, 
BCG-Glaxo, is genetically close to the BCG-Denmark 
strain. In a comparison between Danish and Glaxo BCG 
strains in UK schoolchildren the immunogenicity was 
similar, and BCG-Glaxo produced larger scars, which 
might correlate with non-specific effects.22,23
The duration of any beneficial non-specific effects of 
BCG vaccination is unknown. The data from Chingleput, 
south India, and from Native Americans in the USA 
both show no difference in non-tuberculosis mortality 
between the vaccine groups at any time since vaccination 
(figure 1).7,9 Our trial found similar null results, 
throughout follow-up and in all age groups (figures 3, 4).
The study size was limited by the data available. Based 
on the rates observed in the placebo group and the median 
follow-up times, we had 80% power to detect HRs of less 
than 0·68 in the northern area and less than 0·74 in the 
southern area, at the 5% level of significance.
All-cause mortality is likely to be harder to influence by 
immune modulation in adults than in young children 
because a smaller proportion of deaths will be due to acute 
infections in the adult population than among children. 
Cause of death was not known for most of the population 
in this study. In the subgroup for whom we had this 
information, there was no evidence of protection against 
communicable disease deaths, but numbers were small, 
and this was a select group who had already survived at 
least 13 years since vaccination. In the wider demographic 
surveillance population from 2004–09, we have previously 
shown that the number of deaths in adults due to 
communicable disease was 419 (46·3%) of 905 deaths, 
with 364 (40·2%) due to non-communicable disease and 
only 47 (5·2%) attributable to external causes (75 [8·3%] 
unknown).18 Over that period, the proportion of deaths 
due to HIV/AIDS decreased sharply (from 42% to 17% of 
deaths) following the roll-out of antiretroviral therapy 
from 2005, but the rates of death due to non-communicable 
and communicable disease other than HIV/AIDS were 
approximately constant.18 In the northern area, the 
proportion of deaths due to HIV/AIDS is likely to have 
been smaller than in the southern area because the 
follow-up period was before the peak of the HIV epidemic.
There is little direct evidence of a non-specific effect of 
BCG vaccination on morbidity in adults. In a trial in 
South African adolescents, it was noted that BCG 
revaccination was associated with a lower incidence of 
upper respiratory tract infections, but this was one of a 
long list of possible adverse events recorded, not a 
prespecified outcome of the trial.24 Two small trials, which 
lack detailed reporting, suggest that BCG vaccination 
confers protection against pneumonia and upper 
respiratory tract infection in older people.25,26 In 2020, an 
interim analysis of a randomised controlled trial in older 
people found reduced infections (HR 0·55 [95% CI 
0·31–0·97]) over 12 months.12
Several reviews have catalogued the effects of BCG 
vaccination on different aspects of the immune system, 
including in in-vitro and mouse studies.27–29 Many results 
are not consistent between studies, but BCG vaccination 
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seems to increase interferon-γ, especially after challenge 
with other antigens.27 More recent studies suggest that 
BCG might act primarily through trained innate 
immunity.28–30 Challenge studies with other infections have 
had mixed results—eg, lower viraemia and no difference in 
antibody concentrations following yellow fever vaccination30 
but more severe symptoms following Plasmodium falciparum 
infection31—and studies show considerable interindividual 
variability in responses.
Although there is little evidence of an effect of BCG 
vaccination on mortality in adults in our results or 
elsewhere, it is well known that the protective effects of 
BCG against tuberculosis vary by setting,5 and there is 
strong evidence from other studies that it does have 
immunomodulatory effects. We await the results of the 
COVID-19 trials with interest.
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